Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.

Zydus Lifesciences and MSN Laboratories launched the first U.S. generic riociguat, in five strengths from 0.5 mg to 2.5 mg, following FDA approval as a generic equivalent of Adempas. The medicine is indicated for adults with PAH and CTEPH, and the companies say the generic launch can expand access; no generic pricing or sales estimates were disclosed. Bayer reported global Adempas sales of approximately EUR 745 million (about USD 850 million) in 2025, while IQVIA does not report riociguat sales.

Analysis

For BAYN, the key risk is a U.S. loss-of-exclusivity shock to Adempas economics, but the global sales figure is a poor proxy for the exposed revenue: U.S. product sales, net pricing, and contribution profit are not disclosed here. Rare-disease use and chronic treatment may support durable demand, while cheaper access could expand treatment rather than simply transfer every prescription from Bayer; the net effect depends on payer substitution and uptake. Zydus and MSN may capture value, but “first to market” does not establish durable share or attractive partner economics. Watch for follow-on entrants, supply reliability, and whether prescribers and specialty pharmacies switch stable patients. Immediate pressure may be limited absent a quantified U.S. exposure; the 1–3 month catalysts are payer/formulary decisions, channel stocking, and Bayer commentary. Over 6–18 months, multiple generic entrants would raise the risk of sharper price and share erosion. The contrarian angle is that headline global sales may exaggerate Bayer’s near-term exposure, while assuming a smooth generic ramp may understate execution and access friction. A sustained BAYN underperformance thesis would be weakened by immaterial U.S. sales exposure, limited generic uptake, or stable Adempas revenue/guidance; accelerated price cuts or additional launches would strengthen it.

Key Decisions for Investors

• Treat this as a modest BAYN-specific negative catalyst, not a standalone short signal. First verify Bayer’s U.S. Adempas revenue/profit exposure and any product-level guidance; the disclosed global figure does not answer that question.
• For the next 1–3 months, monitor payer coverage, pharmacy substitution, competitor entry, and BAYN commentary. Escalate to a relative short only if evidence shows meaningful U.S. switching or Bayer reduces product expectations; use a defined catalyst window rather than extrapolating global sales.
• Do not infer a clear long in Zydus or MSN from launch status alone. Verify commercial rights and profit split, launch inventory, supply performance, and realized pricing before underwriting earnings contribution.
• Falsifiers: Bayer reports limited U.S. exposure or stable product expectations; generic access fails to translate into switching; or supply constraints delay uptake. A second generic launch or visible formulary displacement would be a negative update for BAYN.